BASF approaches Evonik as Parmantier rates Evonik stock Hold

Published on 10/09/2026 at 12:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Parmantier set a EUR 20.50 target on October 6, 2026. Evonik stock costs EUR 21.24 on October 9, 2026 after EUR 21.06, plus 0.85 percent.

Key points in brief

BASF confirmed exploratory contacts with Evonik on September 25, 2026, while Evonik said no talks were taking place.
Parmantier & Cie. rated Evonik Hold and set a EUR 20.50 target on October 6, 2026.
Evonik posted adjusted EBITDA of EUR 630.00 million in the second quarter of 2026, up 24.00 percent year over year.
Evonik stock was EUR 21.24 at Lang & Schwarz on October 9, 2026, plus 0.85 percent versus the EUR 21.06 prior close.

Architektur-CGI-Render eines modernen Chemiekonzern-Campus mit Glas-Stahl-Fassade und Solaranlage — Evonik Industries DE000EVNK013 als Architektur-Render eines modernen Konzernhauptsitzes mit Glasfassade und Solaranlage, Illustration mit AI erstellt.

BASF had approached Evonik regarding a voluntary public takeover offer for all shares, a move confirmed by EQS News on September 25, 2026. The same day, Reuters reported that BASF said the outcome of exploratory talks was open, while Evonik said no discussion was underway. On October 6, 2026, Parmantier & Cie. rated Evonik Hold with a EUR 20.50 target.

Takeover interest meets a Hold rating

The valuation debate now has two distinct reference points. The EUR 20.50 target from Parmantier & Cie. is EUR 0.74 below the Lang & Schwarz price of EUR 21.24 on October 9, 2026, while the takeover approach remains non-binding and carries no agreed offer price.

Finanznachrichten reported that the Parmantier report dated October 6, 2026 covered the European chemicals cycle and placed Evonik on Hold with a 12-month target of EUR 20.50. Its report described restructuring, operating leverage, portfolio separation and consolidation as key variables for the sector.

Three dated events shape the story

On July 8, 2026, Evonik said it would invest USD 100.00 million over five years to modernize pharmaceutical active-ingredient production in Lafayette, Indiana, according to its investor relations page. On August 4, 2026, adjusted EBITDA reached EUR 630.00 million in the second quarter, up 24.00 percent year over year, as reported in the Yahoo Finance transcript. On September 25, 2026, BASF's approach covered all Evonik shares, while RAG-Stiftung held 43.00 percent of Evonik, according to Reuters.

What does the target imply?

The target sits below the current euro quote, but the operating comparison is stronger than the rating label alone suggests. Evonik's adjusted EBITDA rose from the first-quarter 2026 level of EUR 482.00 million to EUR 859.00 million in the second quarter of 2026 in the standardized financial data, while net income was EUR 84.00 million in the second quarter. The earnings call also linked the improvement to higher volumes and prices, each contributing 7.00 percent.

Next reporting dates are set

Evonik's investor relations calendar schedules third-quarter 2026 reporting for November 3, 2026 and fourth-quarter 2026 reporting for March 4, 2027. The November event is the next reporting date explicitly listed by the company.

Evonik stock stays above the target

Evonik stock was trading at EUR 21.24 at Lang & Schwarz on October 9, 2026 at 12:27 p.m. CEST, up 0.85 percent versus the prior close of EUR 21.06 on October 8, 2026. The finance quote showed a market capitalization of EUR 9.9 billion and a 52-week range of EUR 12.49 to EUR 21.54 as of October 9, 2026. The further course of trading is shown by the continuously updated real-time quote of Evonik stock.